InBios Obtains BARDA Funding to Develop Point-of-Care COVID-19 Test
The Partnership will Support Development of a Lateral Flow Serodiagnostic Test to Identify Those Suspected to be Infected with SARS-CoV-2
SEATTLE, April 30, 2020 /PRNewswire-PRWeb/ -- InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it had been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG Rapid Test, a point-of-care test for detection of SCoV-2 specific IgM/IgG antibodies.
The lateral flow serodiagnostic test will use blood products, from finger-prick samples, to identify people infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay will detect SARS-CoV-2 reactive antibodies as host biomarkers.
Under the agreement, InBios will acquire reagents, including patient samples, develop product kits and carry out performance studies to validate the assay design for Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA). Support from BARDA is expected to accelerate the progress toward EUA submission. Earlier this month, InBios received EUA for its Smart DetectTM SARS-CoV-2 rRT-PCR Kit.
"As we all know, time is of the essence during this pandemic, and a robust serological test is needed to quickly and easily identify symptomatic, as well as high-risk asymptomatic, individuals who can be carriers responsible for a large percentage of person-to-person transmission," said Dr. Syamal Raychaudhuri, InBios' chief scientific officer. "This funding from BARDA enables InBios to rapidly mobilize to develop this test for the EUA purpose."
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00090.
For more information about InBios COVID-19 tests, visit: http://www.inbios.com/covid-19/.
For more information on COVID-19, please visit http://www.cdc.gov or http://www.who.int.
About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic devices for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, our superior quality products are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including an FDA Emergency Use Authorization for our Smart DetectTM SARS-CoV-2 rRT-PCR Kit and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com.
SOURCE InBios International, Inc.
Share this article